News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2021
-
Dec 27, 2021
Chugai Signs Joint Research Agreement with NCC for Asian International Collaborative Prospective Study A-TRAIN
[PDF 393KB] -
Dec 24, 2021
Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus
[PDF 142KB] -
Dec 17, 2021
Notice of Board of Director’s Resolution on Application for New Market Segment “Prime Market”
[PDF 88KB] -
Dec 17, 2021
Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenhouse Gas Reduction Target
[PDF 369KB] -
Dec 16, 2021
Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy
[PDF 393KB] -
Dec 16, 2021
Update on the Development of Oral COVID-19 Drug Candidate AT-527 in Japan
[PDF 269KB] -
Dec 13, 2021
Chugai Files for Additional Indication of Actemra for COVID-19 Pneumonia in Japan
[PDF 341KB] -
Dec 13, 2021
Interim Data from Phase III HAVEN 6 Study Demonstrate Safety and Efficacy Profile of Chugai’s Hemlibra in People with Moderate or Mild Hemophilia A
[PDF 417KB] -
Dec 10, 2021
Chugai Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma
[PDF 405KB] -
Dec 08, 2021
Chugai’s Actemra/RoActemra Approved by the European Commission to Treat Patients with Severe COVID-19
[PDF 362KB] -
Dec 07, 2021
CHMP Recommends EU Approval of Chugai’s Actemra/RoActemra to Treat Patients with Severe COVID-19
[PDF 234KB] -
Dec 03, 2021
Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai’s Osteoporosis Agent Edirol
[PDF 408KB] -
Dec 01, 2021
Chugai Launches a New Educational Website “So-Zo LABO” Aiming for a Society that Embraces Diversity
[PDF 496KB] -
Nov 25, 2021
Anti-Cancer Agent Herceptin Approved for Additional Indication of Salivary Gland Cancer
[PDF 318KB] -
Nov 18, 2021
Personnel Changes
[PDF 260KB] -
Nov 17, 2021
Atea Announces Update on Collaboration with Roche for AT-527
[PDF 250KB] -
Nov 16, 2021
Chugai Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic Profile to Identify TMB-High Tumors
[PDF 507KB] -
Nov 16, 2021
Chugai Hosted Discussion Series to Drive Quality Cancer Care in Developing Countries in Asia in Partnership with City Cancer Challenge
[PDF 402KB] -
Nov 15, 2021
Chugai Continuously Selected in the “DJSI World,” a Global ESG Investment Index
[PDF 357KB] -
Nov 12, 2021
Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpatient Setting
[PDF 91KB] -
Nov 11, 2021
Chugai Files for Additional Indication of Hemlibra for Treatment of Acquired Hemophilia A
[PDF 482KB] -
Nov 05, 2021
The Antibody Cocktail, Ronapreve Approved for Additional Indication as a Preventive Treatment of Symptomatic COVID-19
[PDF 354KB] -
Oct 27, 2021
Completion of Enrollment in Phase III Comparative Study for Investigational Regenerative Cellular Medicine (gMSC®1) for Knee Chondrogenesis Using Allogeneic 3D Artificial Tissue of MSC
[PDF 350KB] -
Oct 22, 2021
Organizational Changes
[PDF 256KB] -
Oct 22, 2021
Chugai Announces 2021 3rd Quarter Results
[PDF 521KB] -
Oct 22, 2021
Notice of Revisions to Financial Forecasts
[PDF 41KB] -
Oct 22, 2021
Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2021
[PDF 93KB] -
Oct 22, 2021
Construction of New Bio API Plant for Early Clinical Trials to Accelerate the Initiation of Clinical Development
[PDF 484KB] -
Oct 20, 2021
Contribution of Para-transit Vehicles to Welfare Services
[PDF 504KB] -
Oct 20, 2021
F. Hoffmann-La Roche Announces Third Quarter Sales 2021
[PDF 178KB] -
Oct 20, 2021
Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting
[PDF 261KB] -
Oct 19, 2021
Chugai Announces the Decision of the Termination of Exclusive License Agreement on OBP-301 (Telomelysin), Oncolytic Viral Immunotherapy
[PDF 68KB] -
Oct 14, 2021
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People with Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 401KB] -
Oct 11, 2021
Chugai Files for Additional Indications of Antibody Cocktail Ronapreve for Prophylaxis of COVID-19 and Treatment of Asymptomatic COVID-19
[PDF 341KB] -
Oct 01, 2021
Chugai Receives Orphan Drug Designation for Hemlibra in Acquired Hemophilia A
[PDF 374KB] -
Sep 30, 2021
Roche Announces Results of REGN-COV 2066 Study for Ronapreve for the Treatment in Patients Hospitalized with COVID-19
[PDF 264KB] -
Sep 27, 2021
Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indication of Systemic Sclerosis
[PDF 138KB] -
Aug 12, 2021
Chugai Launches Evrysdi Dry Syrup 60 mg for the Treatment of Spinal Muscular Atrophy
[PDF 128KB] -
Aug 02, 2021
Chugai Launches FoundationOne Liquid CDx Cancer Genomic Profile as the First Blood-based Comprehensive Genomic Profiling Test for Solid Tumors in Japan
[PDF 300KB] -
Jul 30, 2021
Chugai Continues to be Listed for All ESG Indices Selected by GPIF
[PDF 199KB] -
Jul 26, 2021
Chugai Announces 2021 Half Year Results
[PDF 411KB] -
Jul 26, 2021
Construction of API Manufacturing Building for Late Stage Clinical Development and Early Commercial Production of Small and Mid-Size Molecule Drugs
[PDF 132KB] -
Jul 26, 2021
Organizational and Personnel Changes
[PDF 284KB] -
Jul 26, 2021
F. Hoffmann-La Roche Announces Half Year Results 2021
[PDF 107KB] -
Jul 19, 2021
The Antibody Cocktail, RONAPREVE for Intravenous Infusion Set Receives the World’s First Regulatory Approval from MHLW for COVID-19
[PDF 119KB] -
Jul 15, 2021
Chugai Released Short Film Featuring Mayu Hotta and Nami Kishida “I Wanted to Understand What I Didn't Understand When I Took That Child on a Trip” -NMOSD Disease Awareness Short Film-
[PDF 262KB] -
Jul 09, 2021
Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia
[PDF 178KB] -
Jul 08, 2021
Disposal of Vaccines for Workplace Vaccination
[PDF 236KB] -
Jul 07, 2021
Chugai Files for Additional Indication of Tecentriq for the Adjuvant Treatment of Non-small Cell Lung Cancer
[PDF 123KB] -
Jun 29, 2021
Chugai Files New Drug Application in Japan for Antibody Cocktail Casirivimab and Imdevimab for the Treatment of COVID-19
[PDF 203KB] -
Jun 28, 2021
Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 195KB] -
Jun 25, 2021
Chugai and ALBERT Jointly Develop Data Scientist Training Program for Pharmaceutical Industry - Promotion of DX through acquisition of data utilization skills including pharmaceutical-specific elements -
[PDF 356KB] -
Jun 25, 2021
Immunosuppressant CellCept, Approved for Additional Indication of Prevention of Graft-Versus-Host Disease in Hematopoietic Stem-Cell Transplantation
[PDF 239KB] -
Jun 25, 2021
Genentech Announces FDA Emergency Use Authorization for Chugai’s Actemra for Hospitalized Patients with COVID-19
[PDF 225KB] -
Jun 23, 2021
Chugai Obtains Regulatory Approval for Evrysdi for the Treatment of Spinal Muscular Atrophy
[PDF 327KB] -
Jun 22, 2021
Chugai Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic Profile to be Used as Companion Diagnostic for MSI-High Tumors
[PDF 298KB] -
Jun 11, 2021
Chugai Files New Drug Application in Japan for Faricimab, the First Bispecific Antibody in Ophthalmology for Diabetic Macular Edema and Neovascular Age-related Macular Degeneration
[PDF 333KB] -
Jun 08, 2021
Chugai Selected as Digital Transformation Stock (DX Stock) 2021
[PDF 219KB] -
May 31, 2021
Chugai Introduces First Cryo-electron Microscopy System in Pharmaceutical Industry in Japan
[PDF 282KB] -
May 20, 2021
Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to be used as a Companion Diagnostic for Olaparib in BRCA-Mutated Prostate Cancer
[PDF 306KB] -
May 19, 2021
Chugai Launches Polivy Intravenous Infusion for the Treatment of Diffuse Large B-cell Lymphoma
[PDF 214KB] -
May 10, 2021
Chugai Reached Agreement with Japanese Government regarding Investigational Antibody Cocktail (casirivimab and imdevimab) for COVID-19
[PDF 20KB] -
May 10, 2021
Chugai Discontinues Marketing of Photodynamic Diagnostic Agent "ALAGLIO® Divided Granules 1.5g"
[PDF 159KB] -
May 06, 2021
Research Collaboration by Chugai, the University of Tokyo and RIKEN on Functional Genome Database Published in Cell
[PDF 198KB] -
Apr 26, 2021
CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 175KB] -
Apr 22, 2021
Chugai Announces 2021 1st Quarter Results
[PDF 668KB] -
Apr 22, 2021
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 115KB] -
Apr 21, 2021
Chugai Supports the Japan Climate Initiative’s Calling to Raise 2030 Greenhouse Gas Emission Reduction Target
[PDF 272KB] -
Apr 21, 2021
F. Hoffmann-La Roche Announces First Quarter Sales 2021
[PDF 107KB] -
Apr 12, 2021
Roche Announces Results of Phase 3 Study for Investigational Antibody Cocktail Casirivimab and Imdevimab for the Prevention of COVID-19
[PDF 187KB] -
Apr 08, 2021
Chugai Conducts Disease Awareness Activities Internally and Externally in Supporting the World Hemophilia Day following the Last Year
[PDF 472KB] -
Mar 31, 2021
Chugai Organizes the Second Workshop on Multidisciplinary Team Care Online for Healthcare Professionals in Cambodia
[PDF 584KB] -
Mar 23, 2021
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 100KB] -
Mar 23, 2021
Position and Policy Regarding Reduction of the Investment Unit
[PDF 22KB] -
Mar 23, 2021
Chugai Obtains Approval for Polivy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
[PDF 216KB] -
Mar 23, 2021
Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile, the First Blood-based Comprehensive Genomic Profiling Test for Solid Tumors in Japan
[PDF 299KB] -
Mar 22, 2021
Performance of Chugai's AI-based Antibody Discovery Technology MALEXA-LI Published in Scientific Reports
[PDF 280KB] -
Mar 22, 2021
Chugai Selected as a “Nadeshiko Brand”
--The proactive approach to diversity is highly evaluated by external organizations-- [PDF 267KB] -
Mar 11, 2021
Chugai Provides Update on the Phase III REMDACTA Study of Actemra Plus Remdesivir in Patients with Severe COVID-19 Pneumonia
[PDF 411KB] -
Feb 19, 2021
Chugai in-licenses New Oral Drug Candidate for COVID-19 from Roche
[PDF 197KB] -
Feb 17, 2021
Chugai Refiles Patent Infringement Lawsuit concerning Edirol Capsules
[PDF 121KB] -
Feb 16, 2021
Chugai Obtains Approval for Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Pemigatinib for Patients with FGFR2 Fusion Positive Biliary Tract Cancer
[PDF 294KB] -
Feb 12, 2021
Chugai Wins the Grand Prize for the Third Time in the 23rd NIKKEI Annual Report Awards
[PDF 297KB] -
Feb 09, 2021
Results of Phase III Clinical Study in Japan for Actemra in COVID-19 Associated Pneumonia
[PDF 198KB] -
Feb 04, 2021
Notice on Change of Chief Executive Officer
[PDF 57KB] -
Feb 04, 2021
Chugai Announces 2020 Full Year Results and Forecasts for 2021
[PDF 544KB] -
Feb 04, 2021
Chugai Announces New Growth Strategy “TOP I 2030”
[PDF 404KB] -
Feb 04, 2021
Notice of Distribution of Retained Earnings
[PDF 90KB] -
Feb 04, 2021
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 90KB] -
Feb 04, 2021
Organizational and Personnel Changes
[PDF 404KB] -
Feb 04, 2021
F. Hoffmann-La Roche Announces Financial Results for fiscal 2020
[PDF 107KB] -
Jan 25, 2021
Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Larotrectinib for NTRK Gene Fusion Positive Solid Tumors
[PDF 325KB] -
Jan 25, 2021
Dissolution of Forerunner Pharma Research
[PDF 259KB] -
Jan 22, 2021
Chugai and Taisho Terminate the Co-Marketing Agreement of Edirol®, a Treatment for Osteoporosis
[PDF 127KB] -
Jan 18, 2021
Chugai Supports the Japan Climate Initiative’s Calling to Raise 2030 Renewable Energy Target
[PDF 380KB] -
Jan 12, 2021
Chugai Conducts Digital Transformation in Manufacturing with IBM Japan to Realize a Digital Plant
[PDF 393KB]